Las Vegas, NV -- (SBWIRE) -- 10/05/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Omeros Corporation (NASDAQ:OMER), Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), Galena Biopharma Inc (NASDAQ:GALE), Amgen, Inc. (NASDAQ:AMGN)
Omeros Corporation (NASDAQ:OMER) managed to keep its fall at -0.68% on above-normal volume of 3.15M shares. The stock settled at $13.14 after floating in a range of $3.65 to $13.76. Its latest price has reached market capitalization of $392.20 million. Its 52-week range has been $12.41 to $13.76. Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system.
Has OMER Found The Bottom and Ready To Move Up? Find Out Here
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) traded down on a volume of 3.12 million, lower than its standard daily volume. Shares have dropped-0.23% to $8.55. Over the last twelve months, the stock has gained 177.6% and faced a worst price of $2.14. Astex Pharmaceuticals, Inc. engages in the discovery and development of small molecule therapeutics with a focus on oncology and hematology using its fragment-based drug discovery platform, Pyramid.
Has ASTX Found The Bottom And Ready To Gain Momentum? Find Out Here
Galena Biopharma Inc (NASDAQ:GALE) settled -4.18% lower at $2.29 on below -normal volume of 3.12M shares during the last trading day. The stock has its 12-month high at $3 and 52-week low price was $1.23. It traded in a range of $2.21 to $2.42 during the last trading day. Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing oncology treatments to address major unmet medical needs to advance cancer care. It is developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide.
Will GALE Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, Amgen, Inc. (NASDAQ:AMGN) was up on low volume, trading at a volume of 3.09M versus its average daily volume of 3.34 million shares. At $112.91, the stock has attained market capitalization of 85.06 billion. Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada.
Will AMGN Continue To Move Higher? Find Out Here
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)